Founded in 2001, Synthetic Biologics, Inc. trades on the NYSE MKT, LLC under the symbol "SYN".
The Company's principal executive offices are located in Rockville, MD.
Synthetic Biologics, Inc. is a biotechnology company focused on the development of biologics for the prevention and treatment of serious infectious diseases. The Company is developing an oral enzyme for the prevention of C. difficile infections, and a series of monoclonal antibody therapies for the treatment of Pertussis and Acinetobacter infections.
In addition, the Company is developing a drug candidate for the treatment of relapsing-remitting multiple sclerosis and cognitive dysfunction in multiple sclerosis.
Current Team (3)Update
Funding Rounds (2) - $16.1MUpdate
EPSRC is a UK government agency that funds research and training in engineering and the physical...
BBSRC invests in bioscience research and training focused on climate change, sustainable food...
155 Gibbs Street, Suite 412
4th Floor for Reception
Rockville, MD 20850